Quris-AI

Company Overview

Snapshot

Founded in January 2020 by Isaac Bentwich and Yossi Haran, Quris-AI operates with 51–200 employees. The company has secured funding across three rounds from 10 investors, with a total capital raised of $37 million. In December 2022, Quris-AI's seed funding grew to $37 million, highlighting significant investor confidence in its AI-powered drug development platform.

Business overview

Quris-AI is an artificial intelligence innovator focused on disrupting the drug development process within the Health Tech & Life Sciences sector. The company's core offering is its Bio-AI Clinical Prediction Platform, designed to accurately predict which drug candidates will safely work in humans. This technology aims to reduce the substantial costs associated with failed clinical trials by leveraging advanced machine learning to test drugs on miniaturized patients-on-a-chip, continuously retraining its algorithms for high predictive accuracy in clinical safety. Quris-AI serves the pharmaceutical industry, providing decision support solutions for drug development.

Strategic signal

In September 2023, pharmaceutical giant Merck expanded its collaboration with Quris-AI, signaling strong industry validation for Quris-AI's Bio-AI Clinical Prediction Platform. This continued partnership underscores the growing recognition of AI's potential to revolutionize drug development by improving clinical safety predictions and reducing the need for traditional testing methods, indicating a positive trajectory for Quris-AI's market adoption and strategic importance.

Company Intelligence Q&A

What is Quris-AI's primary focus?

Quris-AI is focused on disrupting the drug development process using its AI-based Bio-AI Clinical Prediction Platform to predict drug safety in humans, thereby reducing failed clinical trials.

When was Quris-AI founded and by whom?

Quris-AI was founded in January 2020 by co-founders Isaac Bentwich and Yossi Haran.

What was a significant funding milestone for Quris-AI?

In December 2022, Quris-AI's seed funding grew to $37 million, with SoftBank leading a $9 million investment.

Which major pharmaceutical company expanded its collaboration with Quris-AI?

In September 2023, pharma giant Merck expanded its collaboration with Quris-AI, indicating continued confidence in its AI drug development platform.

What award did Quris-AI receive in 2022?

In August 2022, Quris-AI earned the Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for its AI-powered drug safety prediction.